- Details
- In this conversation, Fred Saad and Alicia Morgans discuss the critical role of bone health in treating patients with metastatic castration-resistant prostate cancer (mCRPC), particularly when using radium. Dr. Saad highlights that while newer cancer treatments like enzalutamide and abiraterone have been effective, they shouldn't overshadow the importance of bone health. He points to the PEACE III...
|
- Details
- Elena Castro and Joaquin Mateo join Alicia Morgans in a conversation on data related to genetic testing, PARP inhibitors, and the data we saw come out of GU ASCO with the PROpel and MAGNITUDE trials and they discuss how this data impacts the use of PARP inhibitors in castrate-resistant prostate cancer (CRPC). Drs. Castro, Mateo, and Morgans discuss this data in terms of next-generation sequencing...
|
- Details
- Christopher Wallis and Zachary Klaassen focus this discussion on the article published in The Lancet titled "Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound)." The authors of this study aimed to assess pain...
|
- Details
- Alicia Morgans is joined by Frank Schumacher to discuss the study results assessing the association of functional outcomes by decision-making approaches in men with metastatic prostate cancer. Dr. Schumacher and colleagues assessed the association of shared decision-making vs. physician- or patient-directed decisions and measurement of patient quality of life, including patient-reported functional...
|
- Details
- Axel Merseburger joins Alicia Morgans to discuss the results from the PRESIDE study presented at ASCO GU 2022. PRESIDE is a randomized, double-Blind, placebo-controlled, Phase 3b study of the efficacy and safety of continuing enzalutamide in chemotherapy-naïve, mCRPC patients treated with docetaxel plus prednisolone once they have progressed on enzalutamide. Clinical data demonstrate that using do...
|
- Details
- In this discussion between Kara Maxwell and Alicia Morgans, Dr Maxwell highlights the role of TP53 in cancer and understanding the Li-Fraumeni syndrome. Inherited germline TP53 pathogenic and likely pathogenic variants (gTP53) cause autosomal dominant multicancer predisposition including Li-Fraumeni syndrome and the work that Drs. Morgans and Maxwell discuss here sought to determine whether gTP53...
|
- Details
- Alicia Morgans speaks with Kim Chi about the MAGNITUDE trial presented at GU ASCO 2022. The Phase III trial investigates the efficacy of combining niraparib, a PARP inhibitor, with abiraterone and prednisone in treating metastatic castration-resistant prostate cancer (mCRPC). The study focuses on patients with and without homologous recombination repair (HRR) gene alterations. Results reveal that...
|
- Details
- Diane Newman hosts Leanne Schimke to explore the complexities of metastatic prostate cancer with a focus on the role of genomics and PARP inhibitors. Dr. Schimke delves into how advancements in genomics are providing new avenues for personalized treatment, although the field lags about a decade behind breast cancer research. She highlights the importance of differentiating between indolent and agg...
|
- Details
- Oliver Sartor joins Alicia Morgans and discusses the evolving landscape of BiTE ® technology applied to prostate cancer therapy. BiTE is a bispecific T-cell engaging antibody that binds on PSMA and CD3 on the T cells to activate the T cells. Bispecific T-cell engagers are a novel approach to tumor immunotherapy. They discuss the current clinical trials landscape and what is maybe on the horizon fo...
|
- Details
- In this UroToday discussion, Daniel Petrylak joins Tom Keane highlighting the ESMO 2021 data on CheckMate 9KD cohort A2. This was the final analysis of nivolumab and rucaparib for chemotherapy- naïve metastatic castration-resistant prostate cancer. Biographies: Daniel P. Petrylak, MD, Professor of Medicine (Medical Oncology) and of Urology; Co-Leader, Cancer Signaling Networks, Yale Cancer Center,...
|
